Intellia Therapeutics (NTLA)

Intellia Therapeutics (NTLA) Financial Statements


Intellia Therapeutics Financial Overview

Intellia Therapeutics's market cap is currently ―. The company's EPS TTM is $-5.367; its P/E ratio is -4.89; Intellia Therapeutics is scheduled to report earnings on August 1, 2024, and the estimated EPS forecast is $-1.21. See an overview of income statement, balance sheet, and cash flow financials.
Sep 23Jun 23Mar 23Dec 22Sep 22
Income Statement-
Total Revenue$ 11.99M$ 13.59M$ 12.61M$ 13.57M$ 13.27M
Gross Profit$ 11.99M$ 13.59M$ 12.61M$ 13.57M-
EBIT$ -122.08M$ -125.16M$ -100.14M$ -115.33M$ -105.53M
EBITDA-$ -130.09M$ -102.66M-$ -103.58M
Net Income Common Stockholders$ -122.08M$ -123.68M$ -100.14M$ -109.97M$ -113.23M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 854.79M$ 908.07M$ 933.54M$ 1.19B$ 828.19M
Total Assets$ 1.24B$ 1.32B$ 1.42B$ 1.49B$ 1.08B
Total Debt$ 118.34M$ 122.33M$ 126.13M$ 130.70M$ 97.65M
Net Debt$ -736.45M$ -785.74M$ -807.41M$ -1.06B$ -730.55M
Total Liabilities$ 205.94M$ 218.35M$ 227.05M$ 1.52B$ 259.51M
Stockholders Equity$ 1.04B$ 1.10B$ 1.19B$ 1.24B$ 824.95M
Cash Flow-
Free Cash Flow-$ -94.72M$ -113.16M$ -99.21M$ -82.76M
Operating Cash Flow$ -101.38M$ -90.42M$ -109.33M$ -95.30M$ -78.53M
Investing Cash Flow$ 79.50M$ -34.44M$ -122.25M$ -24.73M$ 47.64M
Financing Cash Flow$ 19.10M$ 1.05M$ 2.22M$ 2.11M$ 23.98M
Currency in USD

Intellia Therapeutics Earnings and Revenue History

Intellia Therapeutics Debt to Assets

Intellia Therapeutics Cash Flow

Intellia Therapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis